1 – 10 of 86
- show: 10
- |
- sort: year (new to old)
- |
- Export
- 2026
- Infection, vaccination and risk of dementia : a proposed immunological model (2026) FRONTIERS IN IMMUNOLOGY. 17.
- 2025
- Safety and immunogenicity of an adjuvanted clostridioides difficile vaccine candidate in healthy adults : a randomized placebo-controlled phase 1 study (2025) JOURNAL OF INFECTIOUS DISEASES. 231(3). p.e511-e520
- A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults (2025) VACCINES. 13(9).
- AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells (2025) FRONTIERS IN IMMUNOLOGY. 16.
- Effectiveness of the XBB.1.5 COVID-19 vaccines against SARS-CoV-2 hospitalisation among adults aged ≥ 65 years during the BA.2.86/JN.1 predominant period, VEBIS Hospital Study, Europe, November 2023 to May 2024 (2025) INFLUENZA AND OTHER RESPIRATORY VIRUSES. 19(3).
- 2024
- Environmental sustainability and antimicrobials : an underestimated problem with far-reaching consequences (2024) INTENSIVE CARE MEDICINE. 50(3). p.453-456
- Epidemiology and molecular typing of multidrug-resistant bacteria in tertiary hospitals and nursing homes in Flanders, Belgium (2024) EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 43(1). p.187-194
- Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study (2024) VACCINES. 12(9).
- Microbiological evaluation of ultraviolet C light-emitting diodes for disinfection of medical instruments (2024) HELIYON. 10(17).
- Safety and immunogenicity of a revaccination with a respiratory syncytial virus prefusion F vaccine in older adults : a phase 2b study (2024) JOURNAL OF INFECTIOUS DISEASES. 229(2). p.355-366